palovarotene (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Fibrodysplasia Ossificans Progressiva

Pending FDA approval for prevention of for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

Pending FDA approval for prevention of for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva (FOP) in females aged ≥8 years or males ≥10 years

Next:

Pharmacology

Mechanism of Action

Selective retinoic-acid receptor gamma (RARγ) agonist for prevention of heterotopic ossification (ie, new bone formation outside of the normal skeletal system) associated with fibrodysplasia ossificans progressiva

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.